tirzepatide to retatrutide vs. for Weight Loss Retatrutide vs. Tirzepatide: What's The

Lost wages and diminished earning capacity compensate for income disruptions caused by Ozempic injuries during active treatment and extending into future years if permanent disabilities impair work performance

Key outcomes: Mean weight loss: 14.9% (vs 2.4% placebo) 86.4% of participants achieved 5% loss (vs 31.5% placebo) 50.5% achieved 15% loss (vs 4.9% placebo) SELECT (Lincoff et al., NEJM 2023) added the cardiovascular signature: in 17,604 non-diabetic adults with prior CV history, semaglutide 2.4 mg reduced MACE (CV death, MI, stroke) by 20% over 3 years

According to Lillys release, the trial met its primary endpoint: participants titrating up to the highest orforglipron dose lost 27.3 lb (12.4%) of body weight at 72 weeks versus about 0.9% weight loss with placebo

The pathogenesis of nonarteritic anterior ischemic optic neuropathy

Preventing Weight Regain with Maintenance Dosing One of the main benefits of a maintenance dose is that it can help stop weight from coming back